Lu AF27139 (compound 1) (p.o.; 3, 10, and 100 mg/kg) reduces intracerebroventricular (icv) administered LPS-primed and BzATP-triggered IL-1β release in the frontal cortex of rats and mice[1].
Assessment of Pharmacokinetics (PK) profile of Lu AF27139 (compound 1) in rat[1].
| dose | Cu, plasma (nM)a | Cu, brain (nM)a | Cu, spinal cord (nM)a |
| (mg/kg, po) | (1 h) | (2 h) | (1 h) | (2 h) | (1 h) | (2 h) |
| T1 | 22.4 ± 4.2 | 22.8 ± 10 | 5.4 ± 2.6 | 6.4 ± 2.0 | 5.20 ± 0.80 | 10.0 ± 2.0 |
a: Free plasma, brain, and spinal cord concentrations of Lu AF27139 in rat were determined by the formula (Ct*f
u), where Ct is the total tissue (plasma, brain, or spinal cord) drug concentration and f
u is the fraction unbound in these tissues as determined by ex vivo equilibrium dialysis. Values are expressed as mean ± SEM for n = 3 animals. f
u, plasma = 0.02 ± 0.00, f
u, spinal cord = 0.07 ± 0.03, and f
u, brain = 0.09 ± 0.03. Values are expressed as mean ± SEM for n ≥ 3 experiments.
| Animal Model: | Male Sprague?Dawley rats (280?350 g); Male C57BL mice (18?25g)[1] |
| Dosage: | 3, 10, and 100 mg/kg |
| Administration: | p.o. |
| Result: | Reduced intracerebroventricular (icv) administered LPS-primed and BzATP-triggered IL-1β release in the frontal cortex of rats and mice. |